Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid

Inclusion Criteria

• •1. Male or female ≥18 years of age at the time of consent and imaging.
• •2. Healthy subjects OR those with confirmed (microbiologically, molecular or serological testing) diagnosis of infection at any body site OR clinical and imaging evidence of suspected infection in any body site with confirmation (microbiologically, molecular or serological testing) anticipated within 72 hours of imaging.
• •OR subjects with confirmed inflammatory (rheumatoid arthritis, idiopathic pulmonary fibrosis, etc) or oncologic (e.g. localized or metastatic tumors) disease and clinically determined not to have infection.
• •3. For subjects with infections:
• •Non mycobacterium tuberculosis infections: received no more than 7 days of effective antibiotic treatment, as judged by the attending and/or principal investigator.
• •OR Mycobacterium tuberculosis or mycobacteroides infections: received no more than 4 weeks of effective treatment. Infection confirmed by positive culture or molecular testing.
• •4. For inpatients, determined by the attending of record to be stable to participate in the study (will be documented in the research records).
• •5. Subject is judged by the investigator to have the initiative and means to be compliant with the protocol.
• •6. Subjects or their legal representatives must have the ability to read, understand and provide written informed consent for the initiation of any study related procedures. Adults lacking capacity will not be enrolled in this study.